Patent intelligence · US
US 12178875
Lymphatic system-directing lipid prodrugs
Lymphatic system-directing lipid prodrugs
Patent details — US 12178875
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2024
- Expiration
- Dec 26, 2044
- Applicant
- Seaport Therapeutics, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K45/06, A61K47/542, A61K47/543
Quick answer
US 12178875 (Lymphatic system-directing lipid prodrugs) is held by Seaport Therapeutics, Inc.. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Seaport Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K45/06, A61K47/542, A61K47/543, A61P, A61P37/02
Frequently asked questions
What is US patent 12178875?
US 12178875 (Lymphatic system-directing lipid prodrugs) is held by Seaport Therapeutics, Inc.. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12178875?
Seaport Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12178875 expire?
Our index shows an expiration date of Dec 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.